Clinical Research On A Randomized Controlled Trial Of The Shuxuetong Injection In The Treatment During The Peri-operation Period Of PCI For Coronary Heart Disease

BackgroundThe coronary heart disease has been one of the major diseases that kill the health of the whole citizens in China. To diagnose and cure this disease is percutaneous coronary intervention (PCI). The main components of the Shuxuetong Injection are hirudin and lumberokinase, including other substance like anti-thromboxane, protein, amino acid etc. It is effective on anticoagulation, thrombolysis, fibrinolysis, anti-platelet-aggregation, regulating lipids, imp-roving the microcirculation, protecting myocardium cells. It can effectively improve the endothelial cells function and fibrinolytic activity, reduce the major adverse cardiovascular events(MACE) after PCI.Object ivesTo objectively assess the clinical efficacy of the Shuxuetong Injection and enhance the deduction that the Shuxuetong Injection protected the patients who had PCI operation from further destruction of the endothelial cells in the culprit vessel where probably the stents should be implanted.Methods60appropriate patients were randomly divided into the Therapy Group and the Control Group. All the patients took the tablets recommended from the international guidelines but the Shuxuetong Injection was added in the Therapy Group. The relative clinical data were collected for statistical analyses after the course of the treatments. The curative judgments nominated as HCTn Cr、CRP、ESR、CKMB、cTNI and chest-pain-improvement. The chest-pain-improvement was digital by NRS and then defined as valid and invalid for the chi-square test. While HCT、Cr、CRP、ESR、CKMB、cTNI used t-test. ResultThe Therapy Group had significant difference from the Control Group according to the statistical analysis (P<0.05). Shuxuetong Injection improves the culprit vessel to recanalizate, on its anticoagulation, anti-platelet-aggregation, pro-fibrinolysis and selectively affecting the formed thrombus. Also Shuxuetong Injection can improve the activity of the endogenous anti-oxidant enzyme, inhibit the lipid peroxidation processes. This helps to effectively improve the endothelial function and the fibrinolytic activity in patients with coronary heart disease, stable the internal environment. Shuxuetong Injection prevents the coronary spasm by inhibiting the inflam-matory substances from releasing.ConclusionThe clinical efficacy of Shuxuetong Injection in curing CHD has to be further support by the clinical trial.